The year of weight-loss drugs
Chancellor Jeremy Hunt raised the prospect of the Bank of England reducing interest rates in 2024 in an interview with the FT, and Novo Nordisk’s drugs for obesity could have a profound effect on healthcare, society and our relationship with food. Plus, part three or our three-part series on a changing India looks at…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like FT News Briefing →
Novo Nordisk, Eli Lilly and the GLP-1 economy
Weight boss? Competition for Novo Nordisk
The Weight Loss Drug Revolution: Transforming Bodies and Reshaping Economies | The Global Brief
Can weight loss drugs reduce healthcare costs?
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.